We are a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to address significant unmet medical needs in oncology.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
I-Mab Announces First Patient Dosed in Phase 1 Clinical Trial of Claudin 18.2 and 4-1BB Bispecific Antibody TJ-CD4B in Solid Tumors in China
I-Mab to Present Phase 2 Clinical Data of CD47 Antibody Lemzoparlimab at ESMO Congress 2022
I-Mab to Host 2022 R&D Day